Recent turbulence in the Hong Kong-listed pharmaceutical sector, driven by interim earnings season, Hang Seng Connect eligibility adjustments, capital rotation, and shifting Fed rate hike expectations, has caused short-term sentiment and risk appetite to fluctuate, temporarily overriding the long-term fundamental factors that typically drive HK stocks. At this juncture, TYK Medicines-B (02410) stands out as a prime example of a company with steadily improving fundamentals but temporarily dampened short-term sentiment. Despite solid business progress, the successful conditional approval of its core drug candidate, and significant insider buying, the stock has been pushed into a discount zone by external pressures and market mood, thereby presenting a potential window for long-term value investors.

Core Drug Gets Green Light, Unlocking Commercial Value

On August 27, TYK Medicines announced that its self-developed next-generation EGFR-TKI, Duxacitinib (TY-9591), had received conditional marketing approval from the NMPA in China. The indication covers first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR 19DEL or L858R mutations with CNS metastases. Historically, while third-generation EGFR-TKIs have significantly extended overall survival in EGFR-mutated lung cancer, their ability to penetrate and control brain metastases has remained a shortcoming. The blood-brain barrier acts as a formidable wall, keeping most drugs out. Even osimertinib falls short of meeting clinical needs for intracranial disease control. From its inception, TY-9591 was designed with a clear objective: to challenge osimertinib's dominance in NSCLC treatment, with brain metastasis as its primary focus. For this indication, Duxacitinib is currently the world's first single-agent to demonstrate superior efficacy over osimertinib in a head-to-head clinical study. At this year's ASCO annual meeting, TYK Medicines presented interim results from the pivotal Phase II study (ESAONA) as a late-breaking abstract (LBA) oral presentation. The data showed an intracranial objective response rate (iORR) of 95.5% for the Duxacitinib arm, significantly higher than the 79.6% observed with osimertinib (P=0.0004), alongside a favorable safety profile with manageable treatment-related adverse events. This achievement has drawn widespread global attention and recognition.

From a clinical perspective, brain metastasis in NSCLC remains a major unmet need. Data indicates China recorded 1.0155 million new lung cancer cases in 2023, with nearly 25% of advanced NSCLC patients having brain metastases at diagnosis. Moreover, as survival improves, the cumulative incidence of brain metastases rises annually, with a natural average survival of just one to two months and a poor prognosis. Conventional standard-of-care options for lung cancer brain metastases have significant limitations: traditional radiotherapy and chemotherapy yield intracranial objective response rates of roughly 23%-45%, with median survival generally ranging from three to six months. The approval of Duxacitinib breaks this critical bottleneck that has constrained long-term overall survival in lung cancer. As the drug scales commercially, it not only challenges osimertinib's leadership and reshapes the domestic lung cancer treatment landscape but also addresses the pressing unmet medical needs in NSCLC and brain metastasis care. Given osimertinib's domestic sales exceeding RMB 8 billion, the large-scale commercial value of Duxacitinib, which focuses on brain metastases, is substantial. Market projections estimate annual peak sales of no less than RMB 3 billion for the domestic EGFR-mutant lung cancer brain metastasis market, and no less than RMB 2 billion annually for the lung cancer EGFR L858R mutation segment.

Major Shareholder Increases Stake, Fundamentals Improving Steadily

As noted earlier, the recent volatility across the HK pharma sector, driven by multiple market factors, has also impacted TYK Medicines' share price. To signal that the stock is undervalued, a major shareholder opted for share purchases to restore market confidence. The company has announced that its Chairman, Executive Director, and President, Wu Yusheng, recently bought shares in the open market, with the possibility of further purchases depending on market conditions, cumulatively capped at HK$5 million. Notably, these acquisitions were funded from the shareholder's own resources, with a commitment to voluntarily lock up the acquired shares for six months from the purchase dates over the next month, during which they will not be sold or otherwise transferred. Generally, major shareholder buying signals strong conviction in the company's future prospects and serves as a key barometer for the secondary market. As the market eventually refocuses on fundamentals, TYK Medicines is well-positioned for a structural rally driven by its robust business outlook.

The company's fundamentals have consistently trended upward in recent years. Beyond its flagship asset Duxacitinib, progress across its pipeline and business development collaborations have drawn considerable market attention. TYK Medicines has been deeply focused on lung cancer and breast cancer. In the breast cancer arena, the company has built a pipeline around CDK targets, including CDK2/4, CDK7, and YAP-TEAD programs, designed to address the full continuum of care for HR+/HER2- breast cancer, from first-line therapy through to resistant disease. In October last year, the company presented early clinical data for three CDK inhibitor candidates as poster presentations at the 2025 ESMO congress. The steady advancement of multiple innovative pipeline assets continues to energize the company's long-term growth and solidify its foundation.

On July 21, TYK Medicines announced a strategic collaboration with Qilu Pharmaceutical. This is not a straightforward License-out arrangement but a deep binding formed by three separate agreements. The transaction covers four key areas: TY-9591 product licensing, manufacturing supply, commercialization, and strategic equity subscription. On the operational front, the parties will cooperate on the development and production of the active pharmaceutical ingredient (API) for TY-9591 in China, as well as its commercialization. TYK Medicines will receive an equity subscription payment and upfront payment totaling RMB 700 million, along with milestone payments of up to RMB 2.06 billion tied to regulatory approvals and indication expansions for TY-9591. For the company, this partnership brings not only validation of its R&D capabilities but also crucial cash flow. According to the announcement, the net proceeds from the equity subscription approximate HK$460 million, with a clearly defined allocation: 50% will fund a Phase II/III trial of TY-0540 as monotherapy for platinum-resistant ovarian cancer, 40% is earmarked for a Phase II/III study of TY-0540 combined with fulvestrant in CDK4/6-resistant breast cancer, and the remaining 10% will bolster working capital. This demonstrates that while advancing commercialization of its lead asset TY-9591, TYK Medicines is also accelerating clinical development of its backup pipeline to build a more comprehensive innovative R&D matrix.

On the manufacturing front, the company is constructing a new solid dosage form facility, adding tablet and capsule production lines. Once completed, annual capacity is projected to reach 150 million tablets or capsules, capable of meeting both clinical trial supply needs and partial commercial production of TY-9591. The first phase is expected to complete GMP certification by Q1 2027, enabling production readiness. Additionally, as disclosed in the interim report, the company obtained a Drug Manufacturing License from the Zhejiang Medical Products Administration in January this year, which is anticipated to positively impact capacity expansion and market development in the long run, laying the groundwork for subsequent commercial manufacturing.

Summary

Against the backdrop of recent pressure on the US dollar's credit standing and increased allocation momentum towards HK equities, the Hong Kong innovative drug sector has been volatile amid internal and external disturbances. However, this environment also marks a critical convergence of capital flows and industry trends, where the realization of innovation value will determine the sector's next direction. Companies demonstrating genuine translation of innovation into value are poised to stand out. Given the potential cash-flow generation from the successful approval of its core drug and steadily improving fundamentals, TYK Medicines' long-term value trajectory aligns well with the prevailing investment climate for HK biotech. Therefore, once market sentiment stabilizes and the sector trend reverses, the stock price is likely to accelerate its valuation recovery and break out of its current trading range, showcasing considerable upward flexibility to market investors.